Repurposing of FDA‐Approved Drugs for Treating Iatrogenic Botulism: A Paired 3D‐QSAR/Docking Approach†
- 27 November 2019
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 15 (2) , 256-262
Abstract
Botulinum neurotoxin (BoNT) is widely used for the treatment of spasticity, focal dystonia, chronic migraine, facial hemispasm, and facial aesthetic treatments. Generally, treatment with botulinum toxin is a safe procedure when conducted by clinicians with expertise, and local side effects are rare and transient. However, occasionally adverse effects can occur due to the spread of the drug to nontargeted muscles and organs, producing dry mouth, fatigue, and flu‐like symptoms, up to signs of systemic botulism, which appears to be more frequent in children treated for spasticity than in adults. In silico 3D‐QSAR and molecular docking studies were performed to build a structure‐based model on selected potent known botulinum neurotoxin type A inhibitors; this was used to screen the US Food and Drug Administration (FDA) database. Thirty molecules were identified as possible light‐chain BoNT/A inhibitors. In this study, we applied a well‐established ligand‐ and structure‐based methodology for the identification of hit compounds among a database of FDA‐approved drugs. The identification of budesonide, protirelin, and ciclesonide followed by other compounds can be considered a starting point for investigations of selected compounds that could bypass much of the time and costs involved in the drug approval process.Keywords
This publication has 34 references indexed in Scilit:
- Pharmacophore-guided lead optimization: The rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloproteaseBioorganic & Medicinal Chemistry Letters, 2009
- Consensus Superiority of the Pharmacophore-Based Alignment, Over Maximum Common Substructure (MCS): 3D-QSAR Studies on Carbamates as Acetylcholinesterase InhibitorsJournal of Chemical Information and Modeling, 2009
- Basic validation procedures for regression models in QSAR and QSPR studies: theory and applicationJournal of the Brazilian Chemical Society, 2009
- Molecular field technology applied to virtual screening and finding the bioactive conformationExpert Opinion on Drug Discovery, 2007
- Identification of a Potent Botulinum Neurotoxin A Protease Inhibitor Using in Situ Lead Identification ChemistryOrganic Letters, 2006
- Optimization of parameters for semiempirical methods IV: extension of MNDO, AM1, and PM3 to more main group elementsJournal of Molecular Modeling, 2004
- A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculationsJournal of Computational Chemistry, 2003
- Studies on the Different Modes of Action of the Anticoagulant Protease Inhibitors DX-9065a and ArgatrobanJournal of Biological Chemistry, 2002
- Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: II. Parameterization and validationJournal of Computational Chemistry, 2002
- Suitability of the PM3‐derived molecular electrostatic potentialsJournal of Computational Chemistry, 1993